share_log

Mangoceuticals | 10-Q: Q3 2024 Earnings Report

Mangoceuticals | 10-Q: Q3 2024 Earnings Report

Mangoceuticals | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/14 13:25

Moomoo AI 已提取核心訊息

Mangoceuticals reported Q3 2024 revenue of $133,368, down 45.6% from $245,160 in Q3 2023, primarily due to delays in marketing activities during migration to a new telehealth platform. Gross profit declined to $82,671 from $144,589 year-over-year, impacted by increased shipping costs and customer acquisition discounts.Operating expenses decreased 5.3% to $1.84 million, with significant reductions in advertising and marketing spend to $251,330 from $720,531. The company recorded interest expense of $241,620 related to Series B Preferred Stock offering. Net loss widened to $2 million compared to $1.8 million in Q3 2023.As of September 30, 2024, Mangoceuticals had $73,912 in cash, down from $739,006 at year-end 2023. The company faces substantial doubt about its ability to continue as a going concern and is evaluating strategic alternatives, including potential business combinations or asset sales. Management expects to require additional funding to support operations over the next 12 months.
Mangoceuticals reported Q3 2024 revenue of $133,368, down 45.6% from $245,160 in Q3 2023, primarily due to delays in marketing activities during migration to a new telehealth platform. Gross profit declined to $82,671 from $144,589 year-over-year, impacted by increased shipping costs and customer acquisition discounts.Operating expenses decreased 5.3% to $1.84 million, with significant reductions in advertising and marketing spend to $251,330 from $720,531. The company recorded interest expense of $241,620 related to Series B Preferred Stock offering. Net loss widened to $2 million compared to $1.8 million in Q3 2023.As of September 30, 2024, Mangoceuticals had $73,912 in cash, down from $739,006 at year-end 2023. The company faces substantial doubt about its ability to continue as a going concern and is evaluating strategic alternatives, including potential business combinations or asset sales. Management expects to require additional funding to support operations over the next 12 months.
Mangoceuticals報告2024年第三季度營業收入爲133,368美元，比2023年第三季度的245,160美元下降了45.6%，主要由於遷移到新遠程醫療平台期間市場活動的延遲。毛利潤從去年的144,589美元下降至82,671美元，受到交通成本上升和客戶獲取折扣的影響。營業費用減少5.3%，降至184萬美元，廣告和市場營銷支出顯著減少，從720,531美元降至251,330美元。該公司記錄了241,620美元的利息費用，涉及B系列優先股發行。淨損失擴大至200萬美元，而2023年第三季度爲180萬美元。截至2024年9月30日，Mangoceuticals的現金爲73,912美元，較2023年底的739,006美元下降。該公司面臨着持續經營能力的重大不確定性，並正在評估戰略替代方案，包括潛在的業務組合或資產銷售。管理層預計在接下來的12個月內需要額外的資金來支持業務。
Mangoceuticals報告2024年第三季度營業收入爲133,368美元，比2023年第三季度的245,160美元下降了45.6%，主要由於遷移到新遠程醫療平台期間市場活動的延遲。毛利潤從去年的144,589美元下降至82,671美元，受到交通成本上升和客戶獲取折扣的影響。營業費用減少5.3%，降至184萬美元，廣告和市場營銷支出顯著減少，從720,531美元降至251,330美元。該公司記錄了241,620美元的利息費用，涉及B系列優先股發行。淨損失擴大至200萬美元，而2023年第三季度爲180萬美元。截至2024年9月30日，Mangoceuticals的現金爲73,912美元，較2023年底的739,006美元下降。該公司面臨着持續經營能力的重大不確定性，並正在評估戰略替代方案，包括潛在的業務組合或資產銷售。管理層預計在接下來的12個月內需要額外的資金來支持業務。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Performant Healthcare
    PHLT
    -- 3.000
    SHL Telemedicine
    SHLT
    -- 1.950
    Simulations Plus
    SLP
    -- 24.290
    Mangoceuticals
    MGRX
    -- 2.380
    Forian
    FORA
    -- 2.000
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點